Artelo Biosciences (ARTL) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting of Stockholders scheduled for December 20, 2024, to be held virtually.
Shareholders are invited to vote on key proposals, with voting available online, by phone, mail, or during the virtual meeting.
Proxy materials, including the Notice, Proxy Statement, and 2023 Annual Report, are accessible online.
Voting matters and shareholder proposals
Election of two Class I directors: R. Martin Emanuele, PhD, and Steven Kelly, both recommended by the Board.
Ratification of MaloneBailey, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Proxyholder authorized to vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting FOR both director nominees and the auditor ratification.
Proxyholder appointed with discretion to vote on additional matters arising at the meeting.
Latest events from Artelo Biosciences
- Biopharma registers 9.8M shares for resale, targeting unmet needs but facing dilution risks.ARTL
Registration filing7 Apr 2026 - Equity line agreement enables up to $50M in funding but poses dilution and market risks.ARTL
Registration filing24 Mar 2026 - Biopharma seeks $10.9M via equity/warrants to fund clinical pipeline amid Nasdaq compliance risks.ARTL
Registration filing24 Mar 2026 - Lead programs show strong clinical progress in cancer anorexia, neuropathy, and anxiety.ARTL
Corporate presentation24 Mar 2026 - Biopharma seeks up to $10.8M via share/warrant offering to fund clinical pipeline, with dilution risk.ARTL
Registration filing23 Mar 2026 - Biopharma seeks $10.8M via stock and warrants to fund clinical pipeline, facing dilution and listing risks.ARTL
Registration filing20 Mar 2026 - Strong clinical advances offset by higher net loss and lower cash reserves in 2025.ARTL
Q4 202524 Feb 2026 - Net loss narrowed, cash runway extends into Q4 2025, and key clinical milestones are expected.ARTL
Q3 20245 Feb 2026 - All proposals passed, with directors re-elected and no shareholder questions submitted.ARTL
AGM 20262 Feb 2026 - Promising clinical pipeline in pain, cancer, and mental health, backed by strong IP and leadership.ARTL
Investor presentation30 Jan 2026